Lymph directing prodrugs offering enhanced oral bioavailability and immune cell targeting
- Detailed Technology Description
- Researchers from the Monash Institute of Pharmaceutical Sciences have developed a novel lymph-directing prodrug technology based on the structure of natural triglyceride.
- *Abstract
-
Researchers from the Monash Institute of Pharmaceutical Sciences have developed a novel lymph-directing prodrug technology based on the structure of natural triglyceride, where the drug is conjugated with the glyceride background in the sn-2 position. The resulting prodrug promotes transport to the intestinal lymph and offers potential to enhance oral bioavailability by avoiding first pass hepatic metabolism and to target lymph or lymphocyte-mediated pathologies. In vivo proof of mechanism has been demonstrated and Monash is now seeking partners to further develop its prodrug technology.
- Country/Region
- USA
For more information, please click Here
